Mutational Processes Molding the Genomes of 21 Breast Cancers

Serena Nik‐Zainal(Wellcome Sanger Institute), Ludmil B. Alexandrov(Wellcome Sanger Institute), David C. Wedge(Wellcome Sanger Institute), Peter Van Loo(Wellcome Sanger Institute), Christopher Greenman(University of East Anglia), Keiran Raine(Wellcome Sanger Institute), David Jones(Wellcome Sanger Institute), Jonathan Hinton(Wellcome Sanger Institute), John Marshall(Wellcome Sanger Institute), Lucy Stebbings(Wellcome Sanger Institute), Andrew Menzies(Wellcome Sanger Institute), Sancha Martin(Wellcome Sanger Institute), Kenric Leung(Wellcome Sanger Institute), Lina Chen(Wellcome Sanger Institute), Catherine Leroy(Wellcome Sanger Institute), Manasa Ramakrishna(Wellcome Sanger Institute), Richard Rance(Wellcome Sanger Institute), King Wai Lau(Wellcome Sanger Institute), Laura Mudie(Wellcome Sanger Institute), Ignacio Varela(Wellcome Sanger Institute), David J. McBride(Wellcome Sanger Institute), Graham R. Bignell(Wellcome Sanger Institute), Susanna L. Cooke(Wellcome Sanger Institute), Adam Shlien(Wellcome Sanger Institute), John Gamble(Wellcome Sanger Institute), Ian Whitmore(Wellcome Sanger Institute), Mark Maddison(Wellcome Sanger Institute), Patrick Tarpey(Wellcome Sanger Institute), Helen Davies(Wellcome Sanger Institute), Elli Papaemmanuil(Wellcome Sanger Institute), Philip J. Stephens(Wellcome Sanger Institute), Stuart McLaren(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), Jon W. Teague(Wellcome Sanger Institute), Göran Jönsson(Lund University), Judy E. Garber(Dana-Farber Cancer Institute), Daniel P. Silver(Dana-Farber Cancer Institute), Penelope Miron(Dana-Farber Cancer Institute), Aquila Fatima(Dana-Farber Cancer Institute), Sandrine Boyault(Centre Léon Bérard), Anita Langerød(Oslo University Hospital), Andrew Tutt(King's College London), John W.M. Martens(Erasmus MC), Samuel Aparício(University of British Columbia), Åke Borg(Lund University), Anne Vincent Salomon(Inserm), Gilles Thomas(Centre Léon Bérard), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Andrea L. Richardson(Brigham and Women's Hospital), Michael S. Neuberger(MRC Laboratory of Molecular Biology), P. Andrew Futreal(Wellcome Sanger Institute), Peter J. Campbell(University of Cambridge), Michael R. Stratton(Wellcome Sanger Institute)
Cited by 1,996Open Access
Full Text

Abstract

All cancers carry somatic mutations. The patterns of mutation in cancer genomes reflect the DNA damage and repair processes to which cancer cells and their precursors have been exposed. To explore these mechanisms further, we generated catalogs of somatic mutation from 21 breast cancers and applied mathematical methods to extract mutational signatures of the underlying processes. Multiple distinct single- and double-nucleotide substitution signatures were discernible. Cancers with BRCA1 or BRCA2 mutations exhibited a characteristic combination of substitution mutation signatures and a distinctive profile of deletions. Complex relationships between somatic mutation prevalence and transcription were detected. A remarkable phenomenon of localized hypermutation, termed "kataegis," was observed. Regions of kataegis differed between cancers but usually colocalized with somatic rearrangements. Base substitutions in these regions were almost exclusively of cytosine at TpC dinucleotides. The mechanisms underlying most of these mutational signatures are unknown. However, a role for the APOBEC family of cytidine deaminases is proposed.


Related Papers